Study shows mirabegron effective and well tolerated for overactive bladder

March 04, 2013

New York, NY, March 4, 2013 - In a new phase III trial mirabegron, a β3-adrenoceptor agonist, given once daily for 12 weeks, reduced the frequency of incontinence episodes and number of daily urinations, and improved urgency and nocturia in adults with overactive bladder (OAB) compared to those in a placebo group. The incidence of common adverse events (hypertension, urinary tract infection, headache, nasopharyngitis) was similar in the mirabegron and placebo groups in this study. Rates of dry mouth and constipation were similar in the drug and placebo groups. The study is published in the Journal of Urology®.

"Mirabegron is a first in class therapeutic agent with a mechanism of action distinct from that of antimuscarinic agents," says urologist Victor W. Nitti, MD, of the NYU Langone Medical Center. "While antimuscarinic agents are the current pharmacological mainstay for OAB, some patients have a suboptimal response or experience side effects such as dry mouth or constipation. The result is that a high proportion of patients on antimuscarinic drugs discontinue therapy, with only 25% remaining on therapy at one year. We need an alternative therapy for some of these patients."

This randomized, parallel group, double-blind phase III study comprising 1329 patients was conducted at 132 sites in the U.S. and Canada. Those eligible for the study voided 8 or more times daily and experienced 3 or more urgency episodes with or without incontinence over a 3-day period. After 2 weeks of receiving placebo, 454 patients were randomized to continue to receive placebo, 442 were given 50 mg mirabegron and 433 received 100 mg mirabegron daily for 12 weeks.

Compared to the placebo group, both mirabegron treatment groups showed statistically significant (p <0.05) reductions from baseline to final visit in the mean number of incontinence episodes and micturitions per 24 hours. Interestingly, the voided volume per micturition more than doubled, from an average of 7.0 ml/micturition to about 18 ml/micturition in the mirabegron groups. This finding supports the hypothesis that unlike antimuscarinic drugs, β3-adrenergic agonists work by promoting urine storage and increasing bladder capacity, according to the authors.

Urgency and nocturia were reduced in those treated with mirabegron compared to placebo. Significant improvements were seen in quality of life measures, and the magnitude of the treatment response was similar to that seen with other OAB agents.

The frequency of dry mouth was low and similar in all groups. Two percent or fewer of each group reported constipation. No significant differences were noted among the groups for any other treatment-emergent adverse event, including acute urinary retention, cardiac arrhythmia, or hypertension, and there were no significant hematologic or serum chemistry abnormalities.

"With its balanced efficacy, safety, and tolerability profile, mirabegron could provide an alternative therapeutic option for OAB, particularly in patients whose OAB is inadequately addressed by current antimuscarinic therapy," says Dr. Nitti.
-end-


Elsevier Health Sciences

Related Incontinence Articles from Brightsurf:

Higher risk of future fecal incontinence after sphincter injuries
The risk of subsequent fecal incontinence and intestinal gas leakage is significantly higher among women who, during childbirth, have suffered a sphincter injury and consequent damage to the anal sphincter muscle, was shown in a new study from the University of Gothenburg.

Kegels: Underused by women to treat and prevent urinary incontinence
Kegels are underused to treat and prevent urinary incontinence, especially during pregnancy and the postpartum period.

Magnetic stimulation dramatically improves fecal incontinence
Painless magnetic stimulation of nerves that regulate muscles in the anus and rectum appears to improve their function and dramatically reduce episodes of fecal incontinence, a debilitating problem affecting about 10% of the population, investigators report.

Does adding therapy before, after surgery for urinary incontinence help?
Adding behavioral and physical therapy before and after surgery for women with stress and urgency urinary incontinence resulted in a small improvement in symptoms compared to women who just had surgery but that difference in symptoms may not be clinically important.

Study shows advantages for stress urinary incontinence surgery
One of the most commonly performed surgeries to treat stress urinary incontinence in women may have better long-term results than another common surgical technique, according to a study led by Mayo Clinic researchers.

Childbirth delivery methods and risk of incontinence, overactive bladder
Pelvic floor disorders such as urinary incontinence and pelvic organ prolapse (when one or more of theĀ pelvic organsĀ drop from their normal position) are associated with childbirth and affect millions of women in the United States.

Poll: Half of women over 50 experience incontinence, but most haven't talked to a doctor
Nearly half of women over 50 say they sometimes leak urine according to a new national poll.

Getting relief from sexual dysfunction and incontinence caused by menopause
Microablative fractional CO2 lasers are energy-based devices designed to help manage troublesome menopause symptoms such as painful sex, dryness, itching/burning, urinary frequency, and incontinence.

Overweight and obesity linked to higher risk of urinary incontinence for women
Being overweight or obese is linked with an increased risk of developing urinary incontinence for young to mid-aged women, according to an Obesity Reviews analysis of all relevant published studies.

WPSI says screen all women annually for urinary incontinence
All women should be screened annually for urinary incontinence, according to new guidelines from the Women's Preventive Services Initiative (WPSI).

Read More: Incontinence News and Incontinence Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.